Gonzalez-Baron M, Vicente J, Martin G, Artal A, Cebreiros I, Garcia-Giron C, Tomas M, Gavilan J, Martorell V, Zamora P
Department of Medicine, Hospital La Paz, Facultad de Medicina, Universidad Autonoma, Madrid, Spain.
Am J Clin Oncol. 1990 Aug;13(4):277-9. doi: 10.1097/00000421-199008000-00001.
Cisplatin and 5-fluorouracil by continuous infusion combination produces a high response rate in squamous-cell carcinoma of the head and neck (SCCHN). Carboplatin (CBDCA) is a cisplatin analogue with lower emetic potential and nephrotoxicity, although the myelosuppression potential is higher. Tegafur (ftorafur, FT) is an analogue of 5-fluorouracil. It is absorbed well in its oral form and has moderate gastrointestinal and hematologic toxicity. This clinical trial tested the association of CBDCA i.v. plus FT p.o. in patients with SCCHN who had not been previously treated. Twenty-one patients were evaluable for response; the overall response was 62% (33% complete response, 29% partial response). Toxicity was moderate in most of the patients, although there was a treatment-related death.
持续输注顺铂和5-氟尿嘧啶联合用药对头颈部鳞状细胞癌（SCCHN）有较高的缓解率。卡铂（CBDCA）是一种顺铂类似物，其致吐潜力和肾毒性较低，尽管骨髓抑制潜力较高。替加氟（呋喃氟尿嘧啶，FT）是5-氟尿嘧啶的类似物。它口服吸收良好，具有中度的胃肠道和血液学毒性。本临床试验测试了未接受过治疗的SCCHN患者静脉注射CBDCA加口服FT的联合用药效果。21例患者可评估缓解情况；总体缓解率为62%（完全缓解率33%，部分缓解率29%）。大多数患者毒性为中度，尽管有1例与治疗相关的死亡。
